Daniel N. Darlington Ph.D.

Daniel N. Darlington PhD founded Shock Therapeutics Biotech in 2017 to advance a discovery he and his research partner Donald Gann MD made in Dr. Gann's lab at University of Maryland School of Medicine and Shock Trauma. Dr. Darlington brings his expertise in physiology and bioanalytics to STBI as Chief Scientific Officer.

  • Dr. Darlington is a Research Physiologist at the US Army Institute of Surgical Research Fort Sam Houston, Texas and has spent a significant portion of his scientific career researching hemorrhagic shock treatments.

  • Dr. Darlington's research interests include: to define the mechanisms that lead to coagulopathy in patients suffering from polytrauma and hemorrhage and to define the mechanisms that lead to irreversible shock after trauma and hemorrhage.

  • Dr. Darlington worked in and ran Dr. Gann's lab for ~30 years leading up to their discovery.

  • He is a member of the editorial board for the journal, Shock.​

  • Dr. Darlington received his B.S. from Pennsylvania State University and went on to receive his Ph.D. in Physiology from the University of Virginia.​

  • He completed his Post-Doctoral Fellowship at University of California, San Francisco under Mary F. Dallman, Ph.D.